| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 09/27/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 09/20/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 09/05/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 08/22/2023 | 121.67% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 08/08/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 07/24/2023 | 191.46% | William Blair | → $71 | Initiates Coverage On | → Outperform |
| 07/14/2023 | — | Guggenheim | Maintains | Buy | |
| 07/14/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy |
| 07/14/2023 | 121.67% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 06/01/2023 | 109.36% | HC Wainwright & Co. | → $51 | Reiterates | → Buy |
| 05/11/2023 | 109.36% | HC Wainwright & Co. | → $51 | Upgrades | Neutral → Buy |
| 03/29/2023 | 47.78% | Guggenheim | → $36 | Reiterates | → Buy |
| 03/29/2023 | -22% | HC Wainwright & Co. | → $19 | Reiterates | → Neutral |
| 11/10/2022 | -42.53% | Goldman Sachs | $8 → $14 | Maintains | Sell |
| 11/10/2022 | -26.11% | Baird | → $18 | Downgrades | Neutral → Underperform |
| 11/03/2022 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/02/2022 | 2.63% | Barclays | $16 → $25 | Upgrades | Underweight → Equal-Weight |
| 11/02/2022 | 80.62% | Cantor Fitzgerald | $39 → $44 | Maintains | Overweight |
| 08/10/2022 | -34.32% | Barclays | $17 → $16 | Maintains | Underweight |
| 08/10/2022 | 302.3% | Wells Fargo | $105 → $98 | Maintains | Overweight |
| 08/10/2022 | — | Raymond James | Downgrades | Market Perform → Underperform | |
| 07/19/2022 | 60.1% | Cantor Fitzgerald | → $39 | Assumes | → Overweight |
| 05/24/2022 | -67.16% | Goldman Sachs | $14 → $8 | Maintains | Sell |
| 05/11/2022 | -42.53% | Goldman Sachs | $16 → $14 | Maintains | Sell |
| 05/11/2022 | -26.11% | Baird | $21 → $18 | Upgrades | Underperform → Neutral |
| 05/10/2022 | -30.21% | Barclays | $21 → $17 | Maintains | Underweight |
| 05/10/2022 | -22% | HC Wainwright & Co. | $25 → $19 | Maintains | Neutral |
| 03/25/2022 | 331.03% | Wells Fargo | $107 → $105 | Maintains | Overweight |
| 03/15/2022 | 253.04% | Citigroup | $114 → $86 | Maintains | Buy |
| 03/01/2022 | 339.24% | Wells Fargo | $118 → $107 | Maintains | Overweight |
| 01/31/2022 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 11/09/2021 | 27.26% | Barclays | $46 → $31 | Maintains | Underweight |
| 08/25/2021 | 367.98% | Citigroup | $118 → $114 | Maintains | Buy |
| 08/12/2021 | — | Raymond James | Downgrades | Market Perform → Underperform | |
| 08/11/2021 | 19.05% | Goldman Sachs | → $29 | Downgrades | Neutral → Sell |
| 08/10/2021 | 248.93% | Cantor Fitzgerald | $71 → $85 | Maintains | Overweight |
| 08/10/2021 | — | Baird | Downgrades | Neutral → Underperform | |
| 07/02/2021 | 191.46% | Cantor Fitzgerald | → $71 | Initiates Coverage On | → Overweight |
| 06/21/2021 | 2.63% | Barclays | $33 → $25 | Downgrades | Equal-Weight → Underweight |
| 01/15/2021 | 216.09% | B. Riley FBR | $138 → $77 | Downgrades | Buy → Neutral |
| 01/07/2021 | — | Wells Fargo | Initiates Coverage On | → Overweight | |
| 12/29/2020 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 12/29/2020 | 105.25% | HC Wainwright & Co. | $84 → $50 | Downgrades | Buy → Neutral |
| 12/29/2020 | 183.25% | Baird | $79 → $69 | Downgrades | Outperform → Neutral |
| 12/23/2020 | 216.09% | Roth Capital | → $77 | Downgrades | Buy → Sell |
| 11/10/2020 | 199.67% | Raymond James | $79 → $73 | Maintains | Outperform |
| 10/06/2020 | 166.83% | Citigroup | → $65 | Initiates Coverage On | → Buy |
| 08/26/2020 | 216.09% | Piper Sandler | → $77 | Initiates Coverage On | → Overweight |
| 08/11/2020 | 224.3% | Raymond James | $72 → $79 | Maintains | Outperform |
| 07/30/2020 | 216.09% | Roth Capital | → $77 | Reinstates | → Buy |
| 07/24/2020 | 220.2% | HC Wainwright & Co. | $62 → $78 | Maintains | Buy |
| 07/16/2020 | 195.57% | Raymond James | → $72 | Initiates Coverage On | → Outperform |
| 07/13/2020 | 187.36% | B. Riley Securities | → $70 | Initiates Coverage On | → Buy |
| 06/09/2020 | 27.26% | WBB Securities | → $31 | Downgrades | Strong Buy → Hold |
| 04/28/2020 | 154.52% | HC Wainwright & Co. | $26 → $62 | Maintains | Buy |
| 04/14/2020 | 6.73% | HC Wainwright & Co. | $24 → $26 | Maintains | Buy |
| 03/12/2020 | -1.48% | HC Wainwright & Co. | $18 → $24 | Maintains | Buy |
| 02/11/2020 | -1.48% | Baird | → $24 | Initiates Coverage On | → Outperform |
| 02/07/2020 | -22% | Guggenheim | → $19 | Initiates Coverage On | → Buy |
| 08/07/2019 | -26.11% | HC Wainwright & Co. | $16 → $18 | Maintains | Buy |
| 04/05/2019 | -38.42% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
What is the target price for Arcturus Therapeutics (ARCT)?
The latest price target for Arcturus Therapeutics (NASDAQ: ARCT) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $51.00 expecting ARCT to rise to within 12 months (a possible 109.36% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arcturus Therapeutics (ARCT)?
The latest analyst rating for Arcturus Therapeutics (NASDAQ: ARCT) was provided by HC Wainwright & Co., and Arcturus Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Arcturus Therapeutics (ARCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Arcturus Therapeutics (ARCT) correct?
While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a reiterated with a price target of $0.00 to $51.00. The current price Arcturus Therapeutics (ARCT) is trading at is $24.36, which is within the analyst's predicted range.